August 12, 2015
A Maryland federal judge has axed Mallinckrodt Inc.'s lawsuit challenging a change to its therapeutic equivalence rating for a generic version of Janssen Pharmaceuticals Inc.'s Concerta, finding no procedural or constitutional violations by the U.S. Food and Drug Administration in a ruling unsealed Wednesday.